MARKET

RDY

RDY

Dr Reddys Labs
NYSE
14.49
+0.14
+0.98%
After Hours: 14.26 -0.23 -1.56% 18:38 02/20 EST
OPEN
14.34
PREV CLOSE
14.35
HIGH
14.63
LOW
14.20
VOLUME
2.12M
TURNOVER
--
52 WEEK HIGH
16.17
52 WEEK LOW
12.26
MARKET CAP
12.06B
P/E (TTM)
19.23
1D
5D
1M
3M
1Y
5Y
1D
Dr. Reddy’s biosimilar for Bristol’s Orencia undergoes FDA review
Seeking Alpha · 2d ago
Dr. Reddy's Laboratories' Biologics License Application For Infusion Formulation For DRL_AB Accepted By FDA For Review
Benzinga · 2d ago
Dr. Reddy’s reports FDA acceptance to review Abatacept BLA
TipRanks · 2d ago
USFDA Accepts Dr. Reddy’s Abatacept Biosimilar BLA for Review
Reuters · 2d ago
DR. REDDY’S ANNOUNCES USFDA ACCEPTANCE TO REVIEW ITS BIOLOGICS LICENSE APPLICATION (BLA) FOR PROPOSED INTERCHANGEABLE BIOSIMILAR, ABATACEPT
Reuters · 2d ago
Dr. Reddy’s Announces USFDA Acceptance to Review Its Biologics License Application (BLA) for Proposed Interchangeable Biosimilar, Abatacept
Barchart · 2d ago
Dr. Reddy’s Buys Progynova HRT Brands in India to Bolster Gynecology Portfolio
TipRanks · 4d ago
Dr. Reddy’s to Buy Progynova and Cyclo-Progynova Trademarks in India for $32.15 Million
Reuters · 4d ago
More
About RDY
Dr. Reddy’s Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.

Webull offers Dr Reddy's Laboratories Ltd (ADR) stock information, including NYSE: RDY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RDY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RDY stock methods without spending real money on the virtual paper trading platform.